mTORC1 activation in podocytes is a critical step in the development of diabetic nephropathy in mice
Open accessThe DOI matches its Crossref record; 77 of the 77 references it cites were found in a registry or an index.
Abstract
Diabetic nephropathy (DN) is among the most lethal complications that occur in type 1 and type 2 diabetics. Podocyte dysfunction is postulated to be a critical event associated with proteinuria and glomerulosclerosis in glomerular diseases including DN. However, molecular mechanisms of podocyte dysfunction in the development of DN are not well understood. Here we have shown that activity of mTOR complex 1 (mTORC1), a kinase that senses nutrient availability, was enhanced in the podocytes of diabetic animals. Further, podocyte-specific mTORC1 activation induced by ablation of an upstream negative regulator (PcKOTsc1) recapitulated many DN features, including podocyte loss, glomerular basement membrane thickening, mesangial expansion, and proteinuria in nondiabetic young and adult mice. Abnormal mTORC1 activation caused mislocalization of slit diaphragm proteins and induced an epithelial-mesenchymal transition-like phenotypic switch with enhanced ER stress in podocytes. Conversely, reduction of ER stress with a chemical chaperone significantly protected against both the podocyte phenotypic switch and podocyte loss in PcKOTsc1 mice. Finally, genetic reduction of podocyte-specific mTORC1 in diabetic animals suppressed the development of DN. These results indicate that mTORC1 activation in podocytes is a critical event in inducing DN and suggest that reduction of podocyte mTORC1 activity is a potential therapeutic strategy to prevent DN.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Although podocytes have high basal levels of autophagy, high mTORC1 activity is also required for these cells to maintain their function”
From Autophagy in kidney homeostasis and disease (2020) · cites this paper as [52]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Ulianich, L., Garbi, C., Treglia, A. S., Punzi, D., Miele, C., Raciti, G. A., Bèguinot, F., Consiglio, E., & Jeso, B. D. (2008) · Journal of Cell Science · doi:10.1242/jcs.017202 · Cited by 114
RetractedTOR signaling in growth and metabolism
Wullschleger, S., Loewith, R., & Hall, M. N. (2006) · Cell · doi:10.1016/j.cell.2006.01.016 · Cited by 5,787
Self-citationUpstream and downstream of mTOR
Hay, N., & Sonenberg, N. (2004) · Genes & Development · doi:10.1101/gad.1212704 · Cited by 4,181
TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling
Inoki, K., Li, Y., Zhu, T., Wu, J., & Guan, K.-L. (2002) · Nature Cell Biology · doi:10.1038/ncb839 · Cited by 3,083
Self-citationThe Rag GTPases Bind Raptor and Mediate Amino Acid Signaling to mTORC1
Sancak, Y., Peterson, T. R., Shaul, Y. D., Lindquist, R. A., Thoreen, C. C., Bar-Peled, L., & Sabatini, D. M. (2008) · Science · doi:10.1126/science.1157535 · Cited by 2,773
Özcan, U., Yilmaz, E., Özcan, L., Furuhashi, M., Vaillancourt, E., Smith, R. O., Görgün, C. Z., & Hotamisligil, G. S. (2006) · Science · doi:10.1126/science.1128294 · Cited by 2,413
Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling
Inoki, K., Li, Y., Xu, T., & Guan, K.-L. (2003) · Genes & Development · doi:10.1101/gad.1110003 · Cited by 1,911
Self-citationKestilä, M., Lenkkeri, U., Männikkö, M., Lamerdin, J., McCready, P., Putaala, H., Ruotsalainen, V., Morita, T., Nissinen, M., Herva, R., et al. (1998) · Molecular Cell · doi:10.1016/s1097-2765(00)80057-x · Cited by 1,866
The Tuberous Sclerosis Complex
Crino, P. B., Nathanson, K. L., & Henske, E. P. (2006) · New England Journal of Medicine · doi:10.1056/nejmra055323 · Cited by 1,793
Boute, N., Gribouval, O., Roselli, S., Benessy, F., Lee, H., Fuchshuber, A., Dahan, K., Gubler, M.-C., Niaudet, P., & Antignac, C. (2000) · Nature Genetics · doi:10.1038/74166 · Cited by 1,444
Research works printed but not linked: 2
- Zhong, Am J Respir Cell Mol Biol.
- Kouraklis, 2006, Oncol Rep., 15, 489
Cited by
Items 301–400 of 544
Autophagy protects podocytes from sublytic complement induced injury
Lv, Q., Yang, F., Chen, K., & Zhang, Y. (2016) · Experimental Cell Research · doi:10.1016/j.yexcr.2016.02.009 · Cited by 25
Han, X., Li, Q., Wang, C., & Li, Y. (2018) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-0630-0173 · Cited by 29
SHIPping out diabetes—Metformin, an old friend among new SHIP2 inhibitors
Lehtonen, S. H. (2019) · Acta Physiologica · doi:10.1111/apha.13349 · Cited by 27
Ablation of PGC1 beta prevents mTOR dependent endoplasmic reticulum stress response
Camacho‐Morales, A., Rodríguez‐Cuenca, S., Blount, M. A., Prieur, X., Barbarroja, N., Fuller, M., Hardingham, G. E., & Vidal‐Puig, A. (2012) · Experimental Neurology · doi:10.1016/j.expneurol.2012.06.031 · Cited by 32
Rangel, É. B., Gomes, S. A., Kanashiro‐Takeuchi, R. M., Saltzman, R., Wei, C., Ruiz, P., Reiser, J., & Hare, J. M. (2018) · Scientific Reports · doi:10.1038/s41598-018-33082-x · Cited by 26
Amin, N. G., Rahim, A. A., Rohoma, K. H., Elwafa, R. A., Dabees, H. M. F., & Elrahmany, S. M. (2024) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-024-01450-5 · Cited by 26
“Additionally, several pathways have been suggested previously for the early prevention of DKD focusing on the pivotal role of mTOR through rapamycin treatment [28] or reducing the number of mTORC1 copies in podocytes [29, 30].”
BackgroundPietrobon, A., Yockell‐Lelièvre, J., Flood, T. A., & Stanford, W. L. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.111048 · Cited by 27
Abdollahi, S., Vajdi, M., Meshkini, F., Vasmehjani, A. A., Sangsefidi, Z. S., Clark, C. C. T., & Soltani, S. (2023) · Nutrition Research · doi:10.1016/j.nutres.2023.03.002 · Cited by 25
Activation of acetyl-CoA synthetase 2 mediates kidney injury in diabetic nephropathy
Lu, J., Li, X. Q., Chen, P. P., Zhang, J. X., Liu, L., Wang, G. H., Liu, X. Q., Jiang, T. T., Wang, M. Y., Liu, W. T., et al. (2023) · JCI Insight · doi:10.1172/jci.insight.165817 · Cited by 27
“Podocytes were pretreated with OSS_128167, a selective inhibitor that increases H3K9 acetylation, and then we treated podocytes with HG. Significant decreases in mRNA expression of raptor induced by ACSS2 inhibitor were reversed by OSS_128167 (Figure 7E).”
Reifsnyder, P. C., Doty, R. A., & Harrison, D. E. (2014) · PLoS ONE · doi:10.1371/journal.pone.0114324 · Cited by 24
“Podocyte-specific activation of TORC induced many features of diabetic nephropathy (DN), and a podocyte-specific knockout of TORC protected hybrid B6/BKS-db/db mice from developing DN [28].”
BackgroundTao, J., Polumbo, C., Reidy, K. J., Sweetwyne, M. T., & Suszták, K. (2013) · Kidney International · doi:10.1038/ki.2013.463 · Cited by 28
Niclosamide ethanolamine improves kidney injury in db/db mice
Han, P., Zhan, H., Shao, M., Wang, W., Song, G., Yu, X., Zhang, C., Ge, N., Yi, T., Li, S., et al. (2018) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2018.08.003 · Cited by 24
Mechanism of progression of diabetic kidney disease mediated by podocyte mitochondrial injury
Su, J., Ye, D., Gao, C., Huang, Q., & Gui, D. (2020) · Molecular Biology Reports · doi:10.1007/s11033-020-05749-0 · Cited by 27
Mechanisms and implications of podocyte autophagy in chronic kidney disease
Njeim, R., Merscher, S., & Fornoni, A. (2024) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00415.2023 · Cited by 23
Pisarek-Horowitz, A., Fan, X., Kumar, S., Rasouly, H. M., Sharma, R., Chen, H. A., Coser, K. R., Bluette, C. T., Hirenallur-Shanthappa, D. K., Anderson, S., et al. (2020) · American Journal Of Pathology · doi:10.1016/j.ajpath.2019.12.009 · Cited by 23
Du, Y., Wu, M. T., Song, S., Bian, Y., & Shi, Y. (2024) · Renal Failure · doi:10.1080/0886022x.2024.2338933 · Cited by 24
“Inhibition of mTORC1 activity alleviates the progression of DKD in diabetic mice [43].”
BackgroundAssociations between structural and functional changes to the kidney in diabetic humans and mice
Powell, D. W., Kenagy, D. N., Zheng, S., Coventry, S. C., Xu, J., Cai, L., Carlson, E. C., & Epstein, P. N. (2013) · Life Sciences · doi:10.1016/j.lfs.2013.06.016 · Cited by 26
“Homeostatic pathways of the podocyte regulated by insulin (Welsh et al., 2010) and mTOR (Godel et al., 2011, Inoki et al., 2011) are disrupted by diabetes and genetic manipulations of these pathways in mouse podocytes mimic DN.”
BackgroundHartner, A., Cordasic, N., Klanke, B., Menendez‐Castro, C., Veelken, R. A., Schmieder, R. E., & Hilgers, K. F. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2014.01.001 · Cited by 22
Tian, J., Wang, Y., Guo, H., & Li, R. (2015) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2015.08.004 · Cited by 22
Zhu, A., Yang, X., Sun, M., Zhang, Z. X., & Li, M. (2015) · Genetics and Molecular Research · doi:10.4238/2015.march.13.9 · Cited by 22
“…in early diabetic nephropathy (Sakaguchi et al., 2006). mTOR is expressed primarily in renal podocytes, resulting in a number of deleterious effects such as hypertrophy of podocytes, which is critical for the development of diabetic nephropathy (Pagtalunan et al., 1997; Inoki et al., 2011).”
BackgroundYuanlin, P., & Dehai, Y. (2018) · 中医杂志:英文版 · doi:10.1016/s0254-6272(18)30921-x · Cited by 22
Prompt apoptotic response to high glucose in SGLT-expressing renal cells
Nilsson, L. M., Zhang, L., Bondar, A. A., Svensson, D., Wernerson, A. M., Brismar, H., Scott, L., & Aperia, A. C. (2019) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00615.2018 · Cited by 22
Das, F., Maity, S., Ghosh‐Choudhury, N., Kasinath, B. S., & Choudhury, G. G. (2019) · Journal of Biological Chemistry · doi:10.1074/jbc.ra118.007023 · Cited by 22
“Deacetylation of S6 kinase in the glomeruli of streptozotocin-induced diabetic rats We and others have reported previously that activation of mTORC1 increased the phosphorylation of S6 kinase in diabetic mice and human kidney (13,14,16,17,41-43).”
BackgroundmTOR in podocyte function: Is rapamycin good for diabetic nephropathy?
Lu, M.-K., Gong, X., & Guan, K. (2011) · Cell Cycle · doi:10.4161/cc.10.20.17686 · Cited by 22
Self-citationHistone modification in podocyte injury of diabetic nephropathy
Wang, S., Zhang, X., Wang, Q., & Wang, R. (2022) · Journal of Molecular Medicine · doi:10.1007/s00109-022-02247-7 · Cited by 22
“Genetic deletion of podocyte-specific TORC1 can suppress progression of DN [39].”
BackgroundGuo, W., Li, H., Li, Y., & Kong, W. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115025 · Cited by 23
Independent role of PP2A and mTORc1 in palmitate induced podocyte death
Kumar, S., & Tikoo, K. (2015) · Biochimie · doi:10.1016/j.biochi.2015.02.009 · Cited by 21
Urinary Angiogenin Reflects the Magnitude of Kidney Injury at the Infrahistologic Level
Tavernier, Q., Mami, I., Rabant, M., Karras, A., Laurent‐Puig, P., Chevet, É., Thervet, É., Anglicheau, D., & Pallet, N. (2016) · Journal of the American Society of Nephrology · doi:10.1681/asn.2016020218 · Cited by 22
“TCMR 21 (7) 5 (7) 2 (3) 5 (8) 8 (11) 0.”
The Effect of Chinese Traditional Medicine Huaiqihuang (HQH) on the Protection of Nephropathy
Zhang, X., Cheng, Y., Zhou, Q., Huang, H., Dong, Y., Yang, Y., Zhao, M., & He, Q. (2020) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2020/2153912 · Cited by 22
“Autophagy also plays an important role in the physiological functions of podocytes [13] and excessive reduction or increase of mTOR activity can cause podocyte damage [44, 45].”
BackgroundYao, Y., Wang, J., Yoshida, S., Nada, S., Okada, M., & Inoki, K. (2016) · Journal of the American Society of Nephrology · doi:10.1681/asn.2015010032 · Cited by 22
Self-citationCardioprotective effects of dietary rapamycin on adult female C57BLKS/J‐Leprdb mice
Reifsnyder, P. C., Ryzhov, S. V., Flurkey, K., Anunciado‐Koza, R. P., Mills, I., Harrison, D. E., & Koza, R. A. (2018) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.13557 · Cited by 21
mTOR pathway: A key player in diabetic nephropathy progression and therapeutic targets
Shi, J., Liu, X., Jiao, Y., Tian, J., An, J., Zou, G., & Zhuo, L. (2024) · Genes & Diseases · doi:10.1016/j.gendis.2024.101260 · Cited by 30
“…13,14 Pharmacological agents, such as rapamycin, that disrupt the mTOR signaling pathway have exhibited encouraging therapeutic outcomes in preclinical experimental models of DN. 15 Consequently, directing interventions toward the mTOR pathway presents considerable promise for the management of DN.”
Xue, R., Zhai, R., Xie, L., Zheng, Z., Jian, G., Chen, T., Su, J., Gao, C., Wang, N., Yang, X., et al. (2020) · Journal of Diabetes Research · doi:10.1155/2020/9309768 · Cited by 22
“Moreover, mTORC1 activation in podocytes played a crucial role in the development of DKD [30].”
BackgroundLipotoxicity, Nutrient-Sensing Signals, and Autophagy in Diabetic Nephropathy
Kume, S., & Maegawa, H. (2020) · JMA Journal · doi:10.31662/jmaj.2020-0005 · Cited by 24
“Although mTORC1 is physiologically essential for cell growth, differentiation, protein translation, and inhibition of autophagy, its hyper-activation was recently reported to be strongly associated with pathogenesis of diabetic podocytopathy (60), (61), ((62)).”
BackgroundRapamycin Slows IgA Nephropathy Progression in the Rat
Tian, J., Wang, Y., Zhou, X., Li, Y., Wang, C., Li, J., & Li, R. (2014) · American Journal of Nephrology · doi:10.1159/000358844 · Cited by 21
Pathophysiology of Diabetic Kidney Disease
Qaz, M., Sawaf, H., Ismail, J., Qazi, H., & Vachharajani, T. J. (2022) · EMJ Nephrology · doi:10.33590/emjnephrol/22-00060 · Cited by 28
Ketone Body Metabolism in Diabetic Kidney Disease
Yamahara, K., Yasuda‒Yamahara, M., Kuwagata, S., Chin‒Kanasaki, M., & Kume, S. (2024) · Kidney360 · doi:10.34067/kid.0000000000000359 · Cited by 19
“19,20 21 – 23 For example, mTORC1 signaling should be suppressed in tubular cells exposed to hypoxia, 24 but this does not occur in diabetic atherosclerosis conditions, such as hyperglycemia and high fatty acids.”
BackgroundYu, F., Hu, M., Wang, X., Li, X., Zhang, B., Lu, X., & Wang, R. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.27448 · Cited by 19
“Diabetic nephropathy (DN) is one of the most serious complications in type 1 and type 2 diabetic patients (Inoki et al., 2011).”
BackgroundRetractedDas, F., Bera, A., Ghosh‐Choudhury, N., Sataranatarajan, K., Kamat, A., Kasinath, B. S., & Choudhury, G. G. (2021) · Cellular Signalling · doi:10.1016/j.cellsig.2021.110072 · Cited by 21
Freis, P., Bollard, J., Lebeau, J., Massoma, P., Fauvre, J., Vercherat, C., Walter, T., Manié, S. N., Roche, C., Scoazec, J., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.15469 · Cited by 19
“As mTORC1 is known to activate ER stress in tuberous sclerosis [25] and diabetes [10, 26, 27] and to be strongly activated in GEP-NET, we investigated the activation of mTORC1 pathway on UPR activation.”
BackgroundMa, L., Li, Y., Yin, P., Kong, F., Guo, J., Shi, H., Zhu, J., Zou, Y., & Ge, J. (2017) · Clinical Science · doi:10.1042/cs20171471 · Cited by 18
The Role of Autophagy in Type 2 Diabetic Kidney Disease Management
Tseng, C.-H., Shah, K. M., Chiu, I., & Hsiao, L. (2023) · Cells · doi:10.3390/cells12232691 · Cited by 21
“The downregulation of AMPK signaling in DN leads to decreased autophagic activity and worse outcomes [29], while the mTOR signaling pathway, which is overactivated in DN, blocks the initiation of autophagy [30,31].”
BackgroundLv, J., Yu, H., Du, S., Xu, P., Zhao, Y., Qi, W., & Wang, X. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-06076-3 · Cited by 19
Autophagy: a novel therapeutic target for kidney diseases
Kume, S., Uzu, T., Maegawa, H., & Koya, D. (2012) · Clinical and Experimental Nephrology · doi:10.1007/s10157-012-0695-2 · Cited by 18
“mentioned earlier are present in glomerular epithelial cells, and are reportedly associated with the regulation of cellular function in glomerular epithelial cells [17–19].”
BackgroundMammalian target of rapamycin complex 1 activation in podocytes promotes cellular crescent formation
Mao, J., Zeng, Z., Xu, Z., Li, J., Jiang, L., Fang, Y., Xu, X., Hu, Z., He, W., Yang, J., et al. (2014) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00018.2014 · Cited by 18
“(12), this is the first report that specific activation of mTORC1”
BackgroundDas, F., Ghosh‐Choudhury, N., Lee, D. Y., Gorin, Y. C., Kasinath, B. S., & Choudhury, G. G. (2018) · PLoS ONE · doi:10.1371/journal.pone.0207285 · Cited by 20
IQGAP1 mediates podocyte injury in diabetic kidney disease by regulating nephrin endocytosis
Liu, Y., Su, H., Ma, C., Ji, D., Zheng, X.-L., Wang, P., Zheng, S., Wang, L., Wang, Z., & Xu, D. (2019) · Cellular Signalling · doi:10.1016/j.cellsig.2019.03.009 · Cited by 18
Regulation of the Homeostatic Unfolded Protein Response in Diabetic Nephropathy
Wang, H., Karnati, S., & Madhusudhan, T. (2022) · Pharmaceuticals · doi:10.3390/ph15040401 · Cited by 19
“DN is associated with the abnormal activation of the mTOR complex (mTORC1), a kinase that senses nutrient availability in podocytes [67,68].”
BackgroundHa, T., Park, H.-Y., Seong, S.-B., & Ahn, H. Y. (2015) · Clinical Hypertension · doi:10.1186/s40885-015-0018-5 · Cited by 18
“In experimental diabetic nephropathy and NS models, activation of rapamycin-sensitive protein kinase complex TORC1, which contributes to multiple cellular processes associated with proteostasis, also triggers UPR activation in podocytes, leading to podocyte injury [30,31].”
BackgroundLiu, T., Jin, Q., Yang, L., Mao, H., Ma, F., Wang, Y., Li, P., & Zhan, Y. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1142276 · Cited by 21
Li, S., Yuan, Q., Cao, N., Guo, W., Yao, L., Jiang-min, F., Ma, J., & Wang, L. (2014) · The Scientific World JOURNAL · doi:10.1155/2014/624573 · Cited by 17
“Introduction Diabetic nephropathy (DN), also identical to intercapillary glomerulonephritis or nodular diabetic glomerulosclerosis, is among the most lethal complications that occur in patients with type 1 or type 2 diabetes mellitus (DM) [1, 2].”
BackgroundRetractedMesangial Cell Mammalian Target of Rapamycin Complex 1 Activation Results in Mesangial Expansion
Nagai, K., Tominaga, T., Ueda, S., Shibata, E., Tamaki, M., Matsuura, M., Kishi, S., Murakami, T., Moriya, T., Abe, H., et al. (2017) · Journal of the American Society of Nephrology · doi:10.1681/asn.2016111196 · Cited by 17
C1-Ten is a PTPase of nephrin, regulating podocyte hypertrophy through mTORC1 activation
Lee, J., Koh, A., Jeong, H., Kim, E., Ha, T., Saleem, M. A., & Ryu, S. H. (2017) · Scientific Reports · doi:10.1038/s41598-017-12382-8 · Cited by 17
Role of mTOR signaling in the regulation of high glucose‑induced podocyte injury
Li, Q., Zeng, Y., Jiang, Q. Y., Wu, C., & Zhou, J. (2019) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2019.7236 · Cited by 18
“Over activation of mTORC1 can also lead to severe pathologic effects, including hallmarks of DN (46).”
BackgroundGene expression-based analysis identified NTNG1 and HGF as biomarkers for diabetic kidney disease
Tang, Y., Dong, X., Zeng, Z., & Feng, Z. (2020) · Medicine · doi:10.1097/md.0000000000018596 · Cited by 21
“Podocyte-specific loss of mTOR causes proteinuria and progressive glomerulosclerosis, and podocyte-specific genetic inhibition of mTOR activation prevents progressive glomerular diseases.([30]) The Hippo pathway regulates cell proliferation, apoptosis, and stemness in response to a wide range of extracellular and intr…”
BackgroundThe cytoprotective role of autophagy in puromycin aminonucleoside treated human podocytes
Kang, Y., Saleem, M. A., Chan, K. W., Yung, B. Y., & Law, H. (2013) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2013.12.015 · Cited by 17
mTORC1 inhibitors rapamycin and metformin affect cardiovascular markers differentially in ZDF rats
Nistala, R., Raja, A., & Pulakat, L. (2017) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/cjpp-2016-0567 · Cited by 17
Xiong, Y., Zhu, W., Xu, Q., Ruze, R., Yan, Z., Li, J., Hu, S., Zhong, M., Cheng, Y., & Zhang, G. (2020) · Obesity Surgery · doi:10.1007/s11695-020-04611-3 · Cited by 17
The role of extracellular vesicles in podocyte autophagy in kidney disease
Sun, B.-C., Zhai, S.-B., Zhang, L., & Sun, G. (2021) · Journal of Cell Communication and Signaling · doi:10.1007/s12079-020-00594-z · Cited by 18
Targeting signaling pathways in glomerular diseases
Hénique, C., & Tharaux, P. (2012) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0b013e328354a598 · Cited by 16
mTOR inhibitors in pancreas transplant: adverse effects and drug-drug interactions
Fernandes-Silva, G., de Paula, M. I., & Rangel, É. B. (2016) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2017.1239708 · Cited by 18
“Tight balance of mTOR activity is crucial for podocyte homeostasis [39,41,53].”
BackgroundMaity, S., Bera, A., Ghosh‐Choudhury, N., Das, F., Kasinath, B. S., & Choudhury, G. G. (2018) · Experimental Cell Research · doi:10.1016/j.yexcr.2018.01.021 · Cited by 16
“In fact, long term treatment of mice with rapamycin showed renal atrophy [31,36].”
BackgroundThe mystery of the ketogenic diet: benevolent pseudo-diabetes
Blagosklonny, M. V. (2019) · Cell Cycle · doi:10.1080/15384101.2019.1644765 · Cited by 18
Pathophysiology of Diabetic Nephropathy
Khoury, C. C., Chen, S., & Ziyadeh, F. N. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-815876-0.00019-x · Cited by 21
Rac1 in podocytes promotes glomerular repair and limits the formation of sclerosis
Asao, R., Seki, T., Takagi, M., Yamada, H., Kodama, F., Hosoe-Nagai, Y., Tanaka, E., Trejo, J. A. O., Nonaka, K., Sasaki, Y., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-23278-6 · Cited by 16
Lu, Q., Hu, X., Hou, Q., Yu, L., Cao, K., Ding, D., Lu, Y., & Dai, C. (2024) · Cellular Signalling · doi:10.1016/j.cellsig.2024.111451 · Cited by 17
Cellular cross-talk drives mesenchymal transdifferentiation in diabetic kidney disease
Chatterjee, A., Tumarin, J., & Prabhakar, S. S. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2024.1499473 · Cited by 18
Cell cycle disorders in podocytes: an emerging and increasingly recognized phenomenon
Zhang, C., & Guo, J. (2025) · Cell Death Discovery · doi:10.1038/s41420-025-02486-w · Cited by 18
“…pathway, known as a primary regulator of cell proliferation and growth, is differentially activated at various stages of podocyte development [36]. mTORC1 regulates cell cycle progression and cell growth by modulating mRNA translation through the phosphorylation of its two down-stream…”
Kassab, B. M., Hussein, H. H., Mahmoud, O. M., & Abdel-Alrahman, G. (2019) · Anatomy & Cell Biology · doi:10.5115/acb.2019.52.2.161 · Cited by 15
Risk factors for rapid kidney function decline in diabetes patients
Xing, J., Huang, L., Ren, W., & Mei, X. (2024) · Renal Failure · doi:10.1080/0886022x.2024.2398188 · Cited by 17
“Proteinuria is the result of podocyte injury caused by elevated blood glucose and hyperfiltration [100]. the proportion of patients with diabetes who develop microalbuminuria is substantial while relatively fewer patients develop macroal-buminuria [101].”
BackgroundLiu, L., Chowdhury, S., Fang, X., Liu, J., & Srikant, C. B. (2014) · FEBS Letters · doi:10.1016/j.febslet.2014.04.030 · Cited by 14
“Such interplay between UPR and mTORC1 has been implicated in glucolipotoxicity-triggered pancreatic b-cell demise as well as in diabetic nephropathy [30,33].”
BackgroundLive or Let Die: Is There any Cell Death in Podocytes?
Braun, F., Becker, J. U., & Brinkkoetter, P. T. (2016) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2016.03.008 · Cited by 19
Fohlen, B., Tavernier, Q., Huynh, T. M., Caradeuc, C., Corre, D. L., Bertho, G., Cholley, B., & Pallet, N. (2017) · EBioMedicine · doi:10.1016/j.ebiom.2017.12.023 · Cited by 15
“In line with this, the activation of other adaptive molecular pathways, such as the mammalian target of rapamycin complexes (MTORC) 1- and 2-mediated signaling pathways, are beneficial in patients with kidney injuries (Canaud et al., 2013; Godel et al., 2011; Inoki et al., 2011), although non-invasive markers of their…”
BackgroundLi, F., Mao, X., Zhuang, Q., Zhao, Z., Zhang, Z., & Wu, H. (2019) · Cell Death and Disease · doi:10.1038/s41419-019-1480-x · Cited by 15
Loss of genome maintenance is linked to mTOR complex 1 signaling and accelerates podocyte damage
Braun, F., Mandel, A. M., Blomberg, L., Wong, M. N., Chatzinikolaou, G., Meyer, D. H., Reinelt, A., Nair, V., Akbar-Haase, R., McCown, P. J., et al. (2025) · JCI Insight · doi:10.1172/jci.insight.172370 · Cited by 13
“Herein lies a fundamental difference from past reports and a potential disease mechanism, as numerous studies have depicted the importance of a tight regulation of mTORC1 for podocyte health and the deleterious effects of both overactivation and repression in disease (10, 24, 26, 43, 53, 54).”
Self-citationCheng, Y., Fan, H., Liu, K., Liu, J., Zou, H., & You, Z. (2023) · Cell Biology International · doi:10.1002/cbin.12002 · Cited by 13
“…rats (Liu et al., 2020), and pharmacological inhibition of mTORC1 activity provides effective protection against diabetic renal complications (Inoki et al., 2011; Tomita et al., 2020) and promotes TFEB into the core to play a role in promoting autophagy‐related gene transcription (Martina et…”
BackgroundIwata, Y., Furuichi, K., Hashimoto, S., Yokota, K., Yasuda, H., Sakai, N., Kitajima, S., Toyama, T., Shinozaki, Y., Sagara, A., et al. (2013) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2013.12.072 · Cited by 13
El-Shazly, A. A. A., Sallam, A.-A. M., El-Hefnawy, M. H., & EL-Mesallamy, H. O. (2018) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2018.11.007 · Cited by 12
Sasaki, H., Takahashi, Y., Ogawa, T., Hiura, K., Nakano, K., Sugiyama, M., Okamura, T., & Sasaki, N. (2019) · EXPERIMENTAL ANIMALS · doi:10.1538/expanim.19-0101 · Cited by 12
Translational Aspects of the Mammalian Target of Rapamycin Complexes in Diabetic Nephropathy
Daher, A. A., Alkhansa, S., Azar, W. S., Rafeh, R. W., Ghadieh, H. E., & Eid, A. A. (2022) · Antioxidants and Redox Signaling · doi:10.1089/ars.2021.0217 · Cited by 13
Association of crumbs homolog-2 with mTORC1 in developing podocyte
Hamano, S., Nishibori, Y., Hada, I., Mikami, N., Ito‐Nitta, N., Fukuhara, D., Kudo, A., Xiao, Z., Nukui, M., Patrakka, J., et al. (2018) · PLoS ONE · doi:10.1371/journal.pone.0202400 · Cited by 11
The pivotal role of glucose transporter 1 in diabetic kidney disease
Zhang, L., Wu, M., Zhang, J., Liu, T., Fu, S., Wang, Y., & Xu, Z. (2024) · Life Sciences · doi:10.1016/j.lfs.2024.122932 · Cited by 13
Turinsky, L., Rehrl, S., Nguyen, C., Benyahia, S., Kuperwasser, N., Vasseur, F., Arevalo, A. R., Rabant, M., Goudin, N., Mesnard, L., et al. (2025) · Science Translational Medicine · doi:10.1126/scitranslmed.adq7825 · Cited by 11
Das, F., Ghosh‐Choudhury, N., Maity, S., Kasinath, B. S., & Choudhury, G. G. (2022) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2022.102246 · Cited by 12
“Targeting mTOR for intervention, we and others have shown beneficial effects of rapamycin in rodent models of diabetic nephropathy (50, 61, 63, 64, 85).”
BackgroundNew insights on stress-induced epithelial phenotypic changes
Pallet, N. (2011) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfr611 · Cited by 11
“Other modulators with broader spectrum, including chemical chaperons such as PBA or the phosphatase inhbitor salubrinal, that inhibits eIF2a dephosphorylation may warrant attention as potential therapies for diabetic nephropathy or cyclosporine nephrotoxicity [15, 20].”
BackgroundThe role of mechanistic target of rapamycin in maintenance of glomerular epithelial cells
Yao, Y., & Inoki, K. (2015) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000000181 · Cited by 12
“To further reveal the pathologic roles of mTORC1 activation in podocyte dysfunction, podocyte-specific TSC1 knockout (podo-TSC1 knockout), where podocytes display aberrant mTORC1 activation, was generated in a nondiabetic mouse background [11].”
BackgroundInfluentialSelf-citationProhibitin Signaling at the Kidney Filtration Barrier
Ising, C., & Brinkkoetter, P. T. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-55330-6_29 · Cited by 12
Maezawa, Y., Cina, D., & Quaggin, S. E. (2012) · Elsevier eBooks · doi:10.1016/b978-0-12-381462-3.00022-7 · Cited by 13
mTORC1 signaling and diabetic kidney disease
Swaroop, V., Ozkan, E. E., Herrmann, L., Thurman, A., Kopasz-Gemmen, O., Kunamneni, A., & Inoki, K. (2024) · Diabetology International · doi:10.1007/s13340-024-00738-1 · Cited by 10
“In non-diabetic mice, ablation of the functional TSC complex in either podocytes or proximal tubular cells displaying cell-specific aberrant mTORC1 activation reca-pitulated many pathological and functional alterations seen in the diabetic kidney [8, 9].”
Self-citationSereno, J., Nunes, S., Rodrigues‐Santos, P., Vala, H., Rocha‐Pereira, P., Fernandes, J. C., Santos‐Silva, A., Teixeira, F. J., & Reis, F. (2014) · BioMed Research International · doi:10.1155/2014/576929 · Cited by 10
van der Wolde, J. W., Haruhara, K., Puelles, V. G., Nikolic‐Paterson, D. J., Bertram, J. F., & Cullen‐McEwen, L. A. (2022) · Cell and Tissue Research · doi:10.1007/s00441-022-03611-2 · Cited by 12
CD44 impacts glomerular parietal epithelial cell changes in the aged mouse kidney
Hamatani, H., Eng, D. G., Hiromura, K., Pippin, J. W., & Shankland, S. J. (2020) · Physiological Reports · doi:10.14814/phy2.14487 · Cited by 10
“…(Nagai et al., 2005) and chronic kidney disease (Lieberthal & Levine, 2009), and mTOR inhibition prevents diabetic glomerular hypertrophy (Inoki et al., 2011). pS6RP expression, a downstream target of mTOR, increases in PECs in FSGS and healthy aging in mice (McNicholas…”
BackgroundMaiello, D., Varone, M., Vicidomini, R., Belli, V., Rosa, M. D., Dama, P., Furia, M., & Turano, M. (2022) · Biomedicines · doi:10.3390/biomedicines10051092 · Cited by 10
Zha, D., & Wu, X. (2022) · Journal of Nephrology · doi:10.1007/s40620-022-01365-2 · Cited by 10
“For example, the adenosine monophosphate (AMP)-activated protein kinase (AMPK) and the mTOR pathways are critical regulators of podocyte function that are affected by intracellular glucose [11, 12, 45].”
BackgroundKoya, D., Kitada, M., Kume, S., & Kanasaki, K. (2013) · Clinical and Experimental Nephrology · doi:10.1007/s10157-013-0908-3 · Cited by 10
“However, podocyte-specific Raptor-heterozygous mice show partial deletion of mTORC1 activity in podocyte and resistance to the development of diabetic nephropathy in both streptozotocin-induced type 1 diabetic mice [26] and type 2 diabetic db/db mice [27].”
BackgroundInfluentialYuan, Y., Zhao, C., An, X., Wu, L., Wang, H., Zhao, M., Bai, M., Duan, S., Zhang, B., Zhang, A., et al. (2016) · Free Radical Research · doi:10.3109/10715762.2016.1155706 · Cited by 10
Kuczkowski, A., & Brinkkoetter, P. T. (2017) · Cell and Tissue Research · doi:10.1007/s00441-017-2619-7 · Cited by 11
“…of a very limited capacity of glomeruli for regeneration and the limited ability of terminally differentiated glomerular podocytes for self-renewal (Grahammer et al. 2013), mTOR signaling acts as critical regulator of cell size control (Fukuda et al. 2012; Gödel et al. 2011; Inoki et al. 2011).”
BackgroundIwata, W., Unoki‐Kubota, H., Kato, H., Shimizu, A., Matsumoto, M., Imasawa, T., Igarashi, A., Matsumoto, K., Noda, T., Terauchi, Y., et al. (2020) · PLoS ONE · doi:10.1371/journal.pone.0229397 · Cited by 11
“Additionally, podocyte-specific Tsc1 knockout mice show features of diabetic nephropathy and mTORC1 hyperactivation is present in podocytes of patients with diabetic nephropathy [27, 28].”
BackgroundResultPolycystic Kidney Disease: ADPKD and ARPKD
Liebau, M. C., & Bergmann, C. (2016) · Springer eBooks · doi:10.1007/978-3-662-52972-0_12 · Cited by 11
Hua, R., Wei, J., Torres, M., He, Y., Li, Y., Sun, X., Wang, L., Inoki, K., & Yoshida, S. (2023) · Journal of Cellular Physiology · doi:10.1002/jcp.30996 · Cited by 9
Self-citation
Metadata
- Authors
- Inoki, K., Mori, H., Wang, J., Suzuki, T., Hong, S., Yoshida, S., Blattner, S. M., Ikenoue, T., Rüegg, M. A., Hall, M. N., Kwiatkowski, D. J., Rastaldi, M. P., Huber, T. B., Kretzler, M., Holzman, L. B., Wiggins, R. C., & Guan, K.-L.
- Affiliations
- University of Michigan (US)
- Life Sciences Institute (SG)
- University of Basel (CH)
- Harvard University (US)
- Brigham and Women's Hospital (US)
- University of Freiburg (DE)
- University Medical Center Freiburg (DE)
- University of California San Diego (US)
- ORCID
- Venue
- Journal of Clinical Investigation
- Published
- 2011-06-01
- Volume
- 121
- Issue
- 6
- Pages
- 2181-2196
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC3104745
- OpenAlex
- W2033798110
- Cited by
- 538
- References
- 77
- Citations by year
- 2026: 13 · 2025: 26 · 2024: 23 · 2023: 36 · 2022: 33 · 2021: 22 · 2020: 48 · 2019: 43 · 2018: 39 · 2017: 39 · 2016: 39 · 2015: 35 · 2014: 44 · 2013: 45 · 2012: 36
- FWCI
- 35.14
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- edoc (University of Basel) (acceptedVersion)
- edoc (University of Basel)
- Funders
- National Institutes of Health (5r01dk083491-09, DK083491)
- National Cancer Institute (R01CA108941)
- National Institute of General Medical Sciences (R01GM051586, GM051586)
- National Institute of Diabetes and Digestive and Kidney Diseases (R01-DK083491, DK-083491, R01DK124709)
- Topics
- Health Sciences › Medicine › Nephrology › Renal Diseases and Glomerulopathies
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Oncology › Renal and related cancers
- Keywords
- diabetic nephropathy, mTORC1, podocytes, podocyte loss, proteinuria, glomerulosclerosis, endoplasmic reticulum stress, epithelial-mesenchymal transition, slit diaphragm proteins, TSC1, chemical chaperones, mesangial expansion, glomerular basement membrane thickening
- MeSH terms
- Mechanistic Target of Rapamycin Complex 1, Regulatory-Associated Protein of mTOR, Tuberous Sclerosis Complex 1 Protein, Animals, Carrier Proteins, Cell Differentiation, Diabetes Mellitus, Type 2, Diabetic Nephropathies, Disease Models, Animal, Endoplasmic Reticulum, Enzyme Activation, Glomerular Mesangium, Male, Membrane Proteins, Mice, Inbred C57BL, Mice, Mutant Strains, Phosphorylation, Protein Processing, Post-Translational, Proteins, Mice, Knockout, Ribosomal Protein S6 Kinases, Sirolimus, Tumor Suppressor Proteins, Multiprotein Complexes, Adaptor Proteins, Signal Transducing, Podocytes, Glomerular Basement Membrane, Mice, TOR Serine-Threonine Kinases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.